Press release content from Business Wire. The AP news staff was not involved in its creation. New Study Presents Evidence of Effectiveness and Safety Of Oleandrin and Phoenix Biotechnology’s PBI-06150 Against SARS-CoV-2 March 17, 2021 GMT An article published last week in the Journal of Biomedicine & Pharmacotherapy ( www.elsevier.com/locate/biopha; Vol 138 (2021) 111457) presents in vitro evidence for significant inhibition of SARS-CoV-2 by oleandrin and a defined extract of N. oleander (developed by Phoenix Biotechnology, Inc. and designated as PBI-06150), as well as in vivo evidence of the safety and efficacy of PBI-06150. ADVERTISEMENT The Journal of Biomedicine & Pharmacotherapy is an open access, peer-reviewed medical journal covering medical applications of pharmacology. It was established in 1956 and is published 10 times a year.